GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
Options Market Statistics: Traders Purchase Large Volume of Pfizer Call Options as Director Buys More Shares
Allurion Stock Soars 70% on Weight-loss Therapy Update
Wall Street Today: S&P 500 Closes at Record, Trump Keeps Appearing on TV
BofA Adds Booz Allen Hamilton and Datadog to Its US 1 List
Live Stock News: Market Waiting to See if the President Says Something Exciting Today
Sales are disappointing, and the market scale is questionable....... The trade of overseas weight-loss drug stocks is cooling down.
Due to disappointing clinical trial results for new drugs and sales data below expectations for two consecutive quarters, the stock prices of Novo-Nordisk A/S and Eli Lilly and Co have fallen from their historical highs. Novo-Nordisk A/S has missed out on the top spot in the European stock market, and stocks related to weight loss drugs have entered bear market territory.